Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor

Ohara,Masahiro; Akimoto,Etsushi; Noma,Midori; Matsuura,Kazuo; Doi,Mihoko; Kagawa,Naoki; Itamoto,Toshiyuki

doi:10.3892/ol.2015.3655

Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor

Authors:
- Masahiro Ohara
- Etsushi Akimoto
- Midori Noma
- Kazuo Matsuura
- Mihoko Doi
- Naoki Kagawa
- Toshiyuki Itamoto
View Affiliations

Affiliations: Department of Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima 734‑8530, Japan, Department of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima 734‑8530, Japan, Kagawa Breast Clinic, Hiroshima 730‑0029, Japan
Published online on: August 28, 2015 https://doi.org/10.3892/ol.2015.3655
Pages: 3286-3292

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aromatase inhibitors have played a central role in endocrine therapy for the treatment of estrogen receptor (ER)‑positive breast cancer in postmenopausal patients. However, prognostic factors for recurrence following such treatment have not been identified. The current study aimed to validate the prognostic value of endocrine‑related progesterone receptor (PgR) status combined with body mass index (BMI). Among 659 consecutive patients with primary breast cancer who underwent curative surgery between 2002 and 2012, 184 postmenopausal patients with ER‑positive (ER+) and human epidermal growth factor receptor type 2‑negative (HER2‑) breast cancer who were treated with adjuvant aromatase inhibitor therapy were assessed. The patients were assigned to groups based on BMI, according to the WHO cut‑off value: ≥25 kg/m2 (high, H) or <25 kg/m2 (low, L). Positive nodal status, negative PgR status, BMI‑H and a high Ki-67 labeling index (≥20%) were found to be significantly associated with a short recurrence‑free interval (RFI) upon univariate analysis (P=0.048, 0.007, 0.027, and 0.012, respectively). The patients were further grouped based on their combined PgR/BMI status. The RFI was significantly shorter in the PgR‑ and/or BMI‑H group compared with that of the PgR+/BMI‑L group (P=0.012). Multivariate analysis revealed PgR‑ tumors and/or BMI‑H and positive nodal status to be independent prognostic factors (P=0.012 and 0.020, respectively). The present findings indicate that PgR/BMI status may serve as a practical tool in the management of ER+ and HER2‑ breast cancer in patients treated with adjuvant aromatase inhibitors.

View Figures

View References

1	Iwase H: Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer. 15:278–290. 2008. View Article : Google Scholar : PubMed/NCBI
2	Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, et al: American society of clinical oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 28:3784–3796. 2010. View Article : Google Scholar : PubMed/NCBI
3	Cardoso F, Harbeck N, Fallowfield L, Kyriakides S and Senkus E: ESMO Guidelines Working Group: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 7): vii11–vii19. 2012.
4	Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol. 26:1059–1065. 2008. View Article : Google Scholar : PubMed/NCBI
5	Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, et al: Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1–98 randomized trial. Ann Oncol. 22:2201–2207. 2011. View Article : Google Scholar : PubMed/NCBI
6	Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, et al: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 29:1531–1538. 2011. View Article : Google Scholar : PubMed/NCBI
7	Horwitz KB and McGuire WL: Oestrogen control of progesterone receptor in human breast cancer: correlation with nuclear processing of oestrogen receptor. J Biol Chem. 253:2223–2228. 1978.PubMed/NCBI
8	Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R and Baum M: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 17:818–826. 2006. View Article : Google Scholar : PubMed/NCBI
9	Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Endo Y, Fujii Y and Kobayashi S: Estrogen receptor-positive breast cancer in Japanese women: Trends in incidence, characteristics and prognosis. Ann Oncol. 22:1318–1325. 2011. View Article : Google Scholar : PubMed/NCBI
10	Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, et al: Body mass index as a prognostic feature in operable breast cancer: The international breast cancer study group experience. Ann Oncol. 15:875–884. 2004. View Article : Google Scholar : PubMed/NCBI
11	Elliot KM, Dent J, Stanczyk FZ, Woodley L, Coombes RC, Purohit A and Palmieri C: Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer. Br J Surg. 101:939–948. 2014. View Article : Google Scholar : PubMed/NCBI
12	Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
13	Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Panel members: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 16:1569–1583. 2005. View Article : Google Scholar : PubMed/NCBI
14	Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B and Senn HJ: 10th St. Gallen conference: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 18:1133–1144. 2007. View Article : Google Scholar : PubMed/NCBI
15	Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Panel members: Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
16	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
17	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
18	National Comprehensive Cancer Network: NCCN Guidelines - Breast Cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed. April 1st–2012
19	WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 363:157–163. 2004. View Article : Google Scholar : PubMed/NCBI
20	The Japanese Breast Cancer Society: General rules for clinical and pathological recording of breast cancer (16th). Kanehara, Tokyo: 2008.
21	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
22	Kai K, Nishimura R, Arima N, Miyayama H and Iwase H: p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: A cohort study. Int J Clin Oncol. 11:426–433. 2006. View Article : Google Scholar : PubMed/NCBI
23	Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T and Okada M: Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer-usefulness for malignant grade of triple-negative breast cancer. Breast. 22:958–963. 2013. View Article : Google Scholar : PubMed/NCBI
24	Sestak I, Distler W, Forbes JF, Dowsett M, Howell A and Cuzick J: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol. 28:3411–3415. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, et al: Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1–98 trial. J Clin Oncol. 30:3967–3975. 2012. View Article : Google Scholar : PubMed/NCBI
26	Seynaeve C, Hille E, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, Putter H, Nortier H, van Nes J, Dirix L and van de Velde C: Impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; Exploratory analysis from the TEAM study. Cancer Res. 70:Abstract S2–S3. 2010. View Article : Google Scholar
27	Goodwin PJ: Obesity and endocrine therapy: Host factors and breast cancer outcome. Breast. 22(Suppl 2): S44–S47. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sendur MA, Aksoy S, Zengin N and Altundag K: Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer. 107:1815–1819. 2012. View Article : Google Scholar : PubMed/NCBI
29	Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C and Speizer FE: Alcohol, height and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 87:1297–1302. 1995. View Article : Google Scholar : PubMed/NCBI
30	Mahabir S, Baer DJ, Johnson LL, Hartman TJ, Dorgan JF, Campbell WS, Clevidence BA and Taylor PR: Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 15:2502–2507. 2006. View Article : Google Scholar : PubMed/NCBI
31	McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, Gilliland F, Stanczyk FZ, Yasui Y and Ballard-Barbash R: Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 21:1961–1966. 2003. View Article : Google Scholar : PubMed/NCBI
32	Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP and Dowsett M: Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 30:2977–2980. 2012. View Article : Google Scholar : PubMed/NCBI
33	Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, et al: Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. Br J Cancer. 109:1522–1527. 2013. View Article : Google Scholar : PubMed/NCBI
34	Sini V, Lunardi G, Cirillo M, Turazza M, Bighin C, Giraudi S, Levaggi A, Piccioli P, Bisagni G, Gnoni R, et al: Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. Br J Cancer. 110:1133–1138. 2014. View Article : Google Scholar : PubMed/NCBI
35	Lønning PE, Haynes BP and Dowsett M: Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. Eur J Cancer. 50:1055–1064. 2014. View Article : Google Scholar : PubMed/NCBI
36	Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP and Dowsett M: Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 30:2977–2988. 2012. View Article : Google Scholar : PubMed/NCBI
37	Arafah BM, Finegan HM, Roe J, Manni A and Pearson OH: Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology. 111:584–588. 1982. View Article : Google Scholar : PubMed/NCBI
38	Brisken C: Progesterone signalling in breast cancer: A neglected hormone coming into the limelight. Nat Rev Cancer. 13:385–396. 2013. View Article : Google Scholar : PubMed/NCBI